SCHEMBL4101732

SCHEMBL4101732

COc1cccc(COc2c(CCl)cccc2OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 4/20 0.56
ABCG2 Q9UNQ0 1/20 0.56
BCHE P06276 7/20 0.48
SMN1; SMN2 Q16637 1/20 0.46
HTR1A P08908 2/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1A P35348 2/20 0.44
ADRA1B P35368 2/20 0.44
KDM4E B2RXH2 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2500056 0.89 SMN1; SMN2 (0.50) ABCB1ABCG2SMN1; SMN2KDM4EL3MBTL1
SCHEMBL8964423 0.84 BCHE (0.68) BCHEKDM4EL3MBTL1MEN1KMT2A
SCHEMBL6550273 0.81 SMN1; SMN2 (0.47) ABCB1ABCG2BCHESMN1; SMN2HTR1A
SCHEMBL3072812 0.80 SMN1; SMN2 (0.55) BCHESMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL4770649 0.80 ABCB1 (0.56) ABCB1ABCG2BCHESMN1; SMN2HTR1A
SCHEMBL4108934 0.80 HTR1A (0.45) BCHESMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL18608388 0.79 SMN1; SMN2 (0.58) BCHESMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL3066643 0.79 SMN1; SMN2 (0.62) SMN1; SMN2HTR1AADRA1DADRA1AADRA1B
SCHEMBL6270354 0.78 ABCB1 (0.57) ABCB1ABCG2SMN1; SMN2KDM4EL3MBTL1
SCHEMBL4369269 0.78 ABCB1 (0.57) ABCB1ABCG2SMN1; SMN2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221829-A1 3,4-Dihydroisoquinolinium Salt Derivatives HANWHA CHEMICAL CORPORATION (KR) 2009-09-03 US disclosed
CN-101208305-A 3,4-dihydroisoquinolinium salt derivatives HANWHA CHEMICAL CORP (KR) 2008-06-25 CN disclosed
EP-1896419-A1 3,4-DIHYDROISOQUINOLINIUM SALT DERIVATIVES HANWHA CHEMICAL CORPORATION (KR) 2008-03-12 EP disclosed
WO-2006129978-A1 3,4-DIHYDROISOQUINOLINIUM SALT DERIVATIVES HANWHA CHEMICAL CORPORATION (KR) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221829-A1 3,4-Dihydroisoquinolinium Salt Derivatives KCNQ3, KCNQ1, KCNQ2 ABCB1 437/4885ABCG2 1521/4885BCHE 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.